Furthermore, the positivity rate of IGF2BP3 in HER2 negative (0-1+) breast cancer patients (19.6%, 27/138) was significantly higher compared to patients with HER2 equivocal (2+) (5.5%, 5/91) and HER2 positive (3+) (2.9%, 2/70) (P<0.001). Here, ERBB2 is linked to breast carcinoma.